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fréquence cardiaque (FC). Les variabilités de la PA systolique (PAS) 
et de l’IP sont étudiées par l’analyse spectrale. La sensibilité du 
baroré exe spontané est exprimée par le gain de la fonction de 
transfert entre la PAS et l’IP.
La double mutation induit le jour comme la nuit une augmentation 
de la PAS et une augmentation de la FC (PAS jour : AT1AMUT 127.9 
± 5.9, AT1AWT 104.9 ± 5.4 mmHg ; PAS nuit AT1AMUT 141.4 ± 6.1, 
AT1AWT 115.2 ± 6.6 mmHg ; FC jour : AT1AMUT 481.3 ± 18.4, AT1AWT 
409.7 ± 6.0 bat/min ; FC nuit AT1AMUT 551.1 ± 14.9, AT1AWT 467.6 
± 5.9 bat/min). L’activité motrice des souris n’est pas modi ée par 
la mutation. L’AT1AMUT présente une augmentation signi cative de 
la variabilité de PAS la nuit qui n’est pas observée chez l’AT1AWT. 
La variabilité de IP est signi cativement réduite par la mutation le 
jour. Le Gain des zones LF et de HF est signi cativement réduit chez 
AT1AMUT, le jour et la nuit.
Cette double mutation, associée à un gain de fonction du récepteur 
AT1A, induit ainsi une élévation de la PA accompagnée d’une 
diminution de la sensibilité du baroré exe spontané. L’élévation 
tensionnelle pourrait résulter d’un mécanisme périphérique, avec 
une vasoconstriction liée à l’activation du récepteur AT1A, ou d’un 
mécanisme central : inhibition du baroré exe par une activation 
des récepteurs AT1A cérébraux. L’AngII est en effet connue pour 
inhiber le baroré exe, ce qui pourrait induire une activation 
sympathique élevant la PA.
* Projet soutenu par l’attribution d’une Allocation Doctorale 
Région Ile-de-France.
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The renin—angiotensin system (RAS) plays a major role in regulating 
the cardiovascular system. Angiotensin II (AngII), the main effector 
of the RAS, is involved in both endothelial and smooth muscle cells 
functions, acting by two receptors, type 1 (AT1R) and type 2 (AT2R). 
If the role of the AT1R has been widely investigated in vivo and in 
vitro, the role of the AT2R remains controversial. It is admitted 
that AT2R induces vasodilation and possesses anti-proliferative 
properties. Nevertheless, recent studies have shown that the AT2R 
is vasoconstrictor in hypertension and has proliferative effects in 
tumors. AT2R has a role in vascular reactivity to  ow (shear stress) 
and in cell growth and migration. Moreover, the AT2R decreases 
MMP-2 and increases elastin. Thus we hypothesized that changes 
in vascular wall mechanical strain, extracellular matrix deposition, 
and MMPs activity could be modulated differentially by the AngII 
receptors.
We investigated the role of the AT2R on the capacity of resistance 
arteries to remodel in response to chronic changes in local blood 
 ow.
We investigated  ow-mediated remodeling in resistance arteries in 
PD123319 (AT2R blocker)-treated rats and in AT2R-knockout mice. 
Second order mesenteric arteries were ligated in vivo, generating 
low  ow (LF) and high  ow (HF) arteries, compared to normal  ow 
(NF) vessels. In these vessels a biochemical (protein expression and 
mRNA level) and a structural study (lumen diameter, intima media 
thickness and media cross-sectional area) will be performed in order 
to determine the mechanism involved in the remodeling.
After 2 weeks, outward hypertrophic remodeling occurred in HF 
arteries (increased diameter and medial cross-sectional area) in 
NaCl treated-rats or wild type mice. Nevertheless, high blood  ow-
induced remodeling in mesenteric resistance arteries failed to occur 
in PD123319-treated-rats and in AT2R-KO mice. Inward eutrophic 
remodeling, which occurred in LF arteries, was not affected to the 
absence of the AT2R or its blockade.
Thus, the diameter enlargement due to a chronic rise in blood  ow 
in resistance arteries involves the AT2R, suggesting a vasodilator and 
trophic effect of the receptor in arteriolar remodeling in vivo.
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A. ACOSTA MARTIN 1, A. PANCHAUD 2, M. CHWASTYNIAK 1, 
B. GALLIS 2, P. AMOUYEL 1, D. GOODLETT 2, F. PINET 1
1 Unité Inserm 744, Institut Pasteur de Lille, Lille, France
2 Medicinal Chemistry, University of Washington, Seattle, USA
Aortic Abdominal Aneurysm (AAA) is characterized by an increase of 
diameter (>1.5 times to reference diameter) and loss of parallelism 
of the vessel wall. This disease is more often asymptomatic and 
its rupture is responsible for 1-4 % of mortality in males older than 
65 years. Surgery treatment is possible in the case of detection by 
echography but no speci c biological markers are available. In order 
to identify markers of AAA, we have established a clinical protocol, 
named CORONA, in which 265 patients undergoing coronary bypass 
grafting were recruited from 2002 to 2006 in CHRU of Lille. For 6.4 % 
of them (n=17), an AAA was detected by abdominal ultrasound after 
the bypass. From the 265 patients included, 98 % of plasma samples, 
89 % of macrophages cultures and 40 % of smooth muscle cells cultures 
were obtained to compare proteomes between aneurismal and non-
aneurismal patients. First, every AAA patient was matched to three 
non-AAA, according to their age, tobacco consumption, arterial 
hypertension, diabetes and dyslipidemia. Then, according to this 
classi cation, the biological and clinical data of the CORONA sample 
set, composed of 68 plasma samples from 17 AAA and 51 non-AAA 
bypass patients, were analyzed by exact nonparametric inference 
tests using StatXact.8 software. Next, proteomic analysis of plasma 
samples by a powerful data independent mass spectrometry method 
was performed in order to obtain qualitative as well as quantitative 
information. The results obtained in the statistical analysis showed 
that there are not important signi cant differences in the biological 
and clinical characteristics between both groups of patients, suggesting 
that the potential biomarkers found in the proteomic analysis will be 
more speci c for AAA than in the case that control samples were from 
completely healthy patients. Regarding plasma proteome analysis, 
around 1000 plasma proteins were identi ed with false positive 
discovery rate < 1 %. From identi ed proteins, one third are multiple 
hits (at least 2 peptides per protein were identi ed), and from 
those around 75 proteins might be involved in AAA pathology (matrix 
proteins, proteases and in ammation proteins). The quanti cation of 
these proteins is still under work.
